Cara Therapeutics | CARA - Operating Profit

Stock Price
3.39
Daily Change
0.17 5.28%
Monthly
-1.45%
Yearly
-80.60%
Q2 Forecast
2.82

Cara Therapeutics reported $-5.94M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Acadia Pharmaceuticals USD 17.39M 18.36M Dec/2025
Alterity Therapeutics Limited AUD -8.07M 302.4K Dec/2025
Assertio Holdings USD -3.05M 569K Sep/2024
Cara Therapeutics USD -5.94M 3.55M Sep/2025
Cassava Sciences USD -13.55M 1.69M Dec/2025
Chugai Pharma JPY 169.01B 12.52B Dec/2025
Cipla INR 9.77B 6.21B Dec/2025
Clal Biotechnology ILS -1.74M 7.46M Dec/2022
Compugen USD 56.04M 63.93M Dec/2025
CSL USD 2.64B 1.97B Dec/2025
Grifols EUR 320.55M 91.01M Dec/2025
Halozyme Therapeutics USD -88.41M 306.33M Dec/2025
J&J USD 6.62B 1.03B Mar/2026
Neurocrine Biosciences USD 227.9M 11.4M Dec/2025
Pacira USD 3.19M 9.96M Dec/2025
Pfizer USD 4.65B 3.99B Dec/2025
RedHill Biopharma USD -4.22M 1.8M Jun/2024
Supernus Pharmaceuticals USD 13.82M 74.01M Dec/2025
Vanda Pharmaceuticals USD -40.66M 29.66M Dec/2024